<rst>
<header>
	<relations>
			<rel name="purpose" type="rst"/>
			<rel name="manner" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">5. Microparticles as an Indicator of Disease Activity</segment>
<segment id="2" parent="1003" relname="span">Microparticles have been attracting increasing attention as potential indicators of eukaryotic cell activation .</segment>
<segment id="3" parent="2" relname="elaboration">They could provide valuable information on inflammatory processes in progress , disease activity , and the response to treatment as well as prognosis as a disease assessment indicator .</segment>
<segment id="4" parent="1005" relname="attribution">Hsu et al. demonstrated</segment>
<segment id="5" parent="1006" relname="span">that release of MPs from platelets</segment>
<segment id="6" parent="5" relname="elaboration">activated with collagen decreased considerably</segment>
<segment id="7" parent="1006" relname="circumstance">after the activity of kinase BTK was inhibited .</segment>
<segment id="8" parent="1008" relname="preparation">Reduction of PMPs numbers in other studies with BTK inhibitor in platelet cultures was associated with a decrease in production and the release of inflammatory cytokines IL-6 and IL-8 .</segment>
<segment id="9" parent="1010" relname="span">A considerable increase in the number of platelet , monocyte , and lymphocyte-derived microparticles</segment>
<segment id="10" parent="9" relname="elaboration">( CD3 , CD19 )</segment>
<segment id="11" parent="1009" relname="same_unit">has been observed in RA patients with high disease activity .</segment>
<segment id="12" parent="1011" relname="joint">Rodrigez-Cario et al. examined the amount of circulating microparticles and their origin in 114 RA patients .</segment>
<segment id="13" parent="1013" relname="span">The total number of MPs in platelet poor plasma was much higher in individuals with arthritis</segment>
<segment id="14" parent="13" relname="elaboration">compared to a group of healthy individuals .</segment>
<segment id="15" parent="1015" relname="joint">The occurrence of different MPs subtypes in this study differed considerably in the RA group</segment>
<segment id="16" parent="1015" relname="joint">and was associated with the clinical course of joint inflammation :</segment>
<segment id="17" parent="1017" relname="joint">The amount of endothelial MPs was associated with the disease duration ,</segment>
<segment id="18" parent="1018" relname="span">the amount of granulocyte MPs was associated with the disease activity</segment>
<segment id="19" parent="20" relname="circumstance">as assessed by DAS28 ,</segment>
<segment id="20" parent="1019" relname="span">whereas the amount of monocyte-derived MPs was associated with the presence of the rheumatoid factor .</segment>
<segment id="21" parent="1020" relname="joint">The amount of MPs was also associated with the presence of traditional cardiovascular risk factors .</segment>
<segment id="22" parent="1022" relname="span">The findings of Cloutier et al. could indicate the possibility</segment>
<segment id="23" parent="1023" relname="span">of using the studies of circulating mpICs</segment>
<segment id="24" parent="23" relname="purpose">to assess RA activity .</segment>
<segment id="25" parent="1025" relname="span">However , different conclusions were presented by van Eijk et al.</segment>
<segment id="26" parent="25" relname="elaboration">based on a study with 24 patients with an early form of RA .</segment>
<segment id="27" parent="1028" relname="span">The disease activity was assessed</segment>
<segment id="28" parent="1029" relname="span">based on the ESR , C-reactive protein</segment>
<segment id="29" parent="28" relname="restatement">( CRP )</segment>
<segment id="30" parent="1027" relname="same_unit">level , and DAS28 score .</segment>
<segment id="31" parent="1033" relname="span">Moreover , the level of serum amyloid-P</segment>
<segment id="32" parent="31" relname="restatement">( SAP )</segment>
<segment id="33" parent="1032" relname="same_unit">and the amount of circulating MPs and MPs</segment>
<segment id="34" parent="1032" relname="elaboration">presenting the C1q complement component was determined in the patients .</segment>
<segment id="35" parent="1036" relname="span">Nine patients were reassessed after an eight-week intensive treatment</segment>
<segment id="36" parent="37" relname="attribution">according to the COBRA</segment>
<segment id="37" parent="1037" relname="span">( COmBination therapy in Rheumatoid Arthritis )</segment>
<segment id="38" parent="1038" relname="span">regimen ,</segment>
<segment id="39" parent="38" relname="elaboration">which included a combined treatment with methotrexate , sulfasalazine , and prednisolone .</segment>
<segment id="40" parent="1040" relname="span">As expected , ESR , CRP , and DAS28 improved as a result of the treatment ;</segment>
<segment id="41" parent="1041" relname="contrast">however , contrary to expectations ,</segment>
<segment id="42" parent="1042" relname="span">neither the amount of circulating MPs , nor MPs with the attached C1q component decreased ,</segment>
<segment id="43" parent="42" relname="elaboration">which suggests the absence of any connection between the activity of inflammation and MPs release and mpIC production .</segment>
<segment id="44" parent="1044" relname="attribution">In a recent paper , Chen demonstrated</segment>
<segment id="45" parent="1045" relname="span">that inhibition of PMPs formation in an animal model of CIA</segment>
<segment id="46" parent="45" relname="elaboration">( collagen-induced arthritis )</segment>
<segment id="47" parent="1046" relname="span">and reduction of circulating PMPs was associated with a clinical decrease in the disease activity</segment>
<segment id="48" parent="47" relname="elaboration">assessed as joint swelling and stiffness .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1001" relname="span"/>
<group id="1003" type="span" parent="1002" relname="span"/>
<group id="1004" type="span" parent="1003" relname="elaboration"/>
<group id="1005" type="span" parent="1004" relname="span"/>
<group id="1006" type="span" parent="1005" relname="span"/>
<group id="1007" type="span" parent="1002" relname="elaboration"/>
<group id="1008" type="span" parent="1007" relname="span"/>
<group id="1009" type="multinuc" parent="1011" relname="background"/>
<group id="1010" type="span" parent="1009" relname="same_unit"/>
<group id="1011" type="multinuc" parent="1008" relname="span"/>
<group id="1012" type="multinuc" parent="1011" relname="joint"/>
<group id="1013" type="span" parent="1012" relname="joint"/>
<group id="1014" type="span" parent="1012" relname="joint"/>
<group id="1015" type="multinuc" parent="1016" relname="preparation"/>
<group id="1016" type="multinuc" parent="1014" relname="span"/>
<group id="1017" type="multinuc" parent="1016" relname="joint"/>
<group id="1018" type="span" parent="1017" relname="joint"/>
<group id="1019" type="span" parent="18" relname="manner"/>
<group id="1020" type="multinuc" parent="1016" relname="joint"/>
<group id="1021" type="multinuc" parent="1020" relname="joint"/>
<group id="1022" type="span" parent="1021" relname="joint"/>
<group id="1023" type="span" parent="22" relname="elaboration"/>
<group id="1024" type="multinuc" parent="1021" relname="joint"/>
<group id="1025" type="span" parent="1024" relname="joint"/>
<group id="1026" type="multinuc" parent="1024" relname="joint"/>
<group id="1027" type="multinuc" parent="1026" relname="joint"/>
<group id="1028" type="span" parent="1027" relname="same_unit"/>
<group id="1029" type="span" parent="27" relname="elaboration"/>
<group id="1030" type="multinuc" parent="1026" relname="joint"/>
<group id="1031" type="span" parent="1030" relname="joint"/>
<group id="1032" type="multinuc" parent="1031" relname="span"/>
<group id="1033" type="span" parent="1032" relname="same_unit"/>
<group id="1034" type="multinuc" parent="1030" relname="joint"/>
<group id="1035" type="multinuc" parent="1034" relname="joint"/>
<group id="1036" type="span" parent="1035" relname="same_unit"/>
<group id="1037" type="span" parent="35" relname="elaboration"/>
<group id="1038" type="span" parent="1035" relname="same_unit"/>
<group id="1039" type="multinuc" parent="1034" relname="joint"/>
<group id="1040" type="span" parent="1039" relname="joint"/>
<group id="1041" type="multinuc" parent="40" relname="concession"/>
<group id="1042" type="span" parent="1041" relname="contrast"/>
<group id="1043" type="span" parent="1039" relname="joint"/>
<group id="1044" type="multinuc" parent="1043" relname="span"/>
<group id="1045" type="span" parent="1044" relname="joint"/>
<group id="1046" type="span" parent="1044" relname="joint"/>
	</body>
</rst>
